Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Black market for Truvada PrEP may undermine treatment adherence in marginalised people living with HIV

The increasing demand for pre-exposure prophylaxis (PrEP) is likely to increase the likelihood that some marginalised individuals living with HIV sell some of their prescribed medication to

Published
13 July 2015
By
Roger Pebody
Scripps Research Institute-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate

HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS. But now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown that, unlike other antiretroviral therapies, a natural compound called Cortistatin A reduces residual levels of virus from these infected dormant cells, establishing a near-permanent state of latency and greatly diminishing the virus’ capacity for reactivation.

Published
11 July 2015
From
Scripps Research Institute
Community-based adherence clubs show high retention in HIV care and treatment adherence

People with HIV who were receiving their HIV treatment outside of health facilities in community-based adherence clubs close to or in their homes demonstrated extremely high rates of

Published
10 July 2015
By
Lesley Odendal
Prompt ART especially important for people with HIV aged 45 and over

Delaying antiretroviral therapy (ART) may have especially serious consequences for middle-aged and elderly HIV-positive people, according to research published in Clinical Infectious Diseases. US investigators found that patients aged

Published
08 July 2015
By
Michael Carter
Could a Subdermal Implant Mean the End of HIV?

Findings published in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

Published
06 July 2015
From
Edge San Francisco
Meet the Khayelitsha compliers club

Communities are bringing HIV monitoring and dispensing out of the clinics and into their homes.

Published
06 July 2015
From
Mail & Guardian
Adherence All-Stars

Diane Peters meets a group of PHAs with “chaotic lifestyles” and finds out how, despite major obstacles, they adhere to their meds.

Published
06 July 2015
From
CATIE
No, Teens Did Not Create a Working Condom That Changes Colors if You Have an STI, and Maybe They Shouldn’t

Last week, the story broke about teens who had invented a new condom that could detect sexually transmitted infections (STIs) and alert a partner by changing colors. But this condom-and-STI-test-wrapped-in-one is not coming soon to a pharmacy near you. It’s an interesting idea, but that’s all it is: just an idea. It’s a thought with theory behind it on how it might work. It has not gotten past the concept stage. There is no operational prototype.

Published
06 July 2015
From
RH Reality Check
NHS England announces annual investment decisions for certain specialised services [including HIV treatment as prevention]

NHS England has today (2 July) set out its planned investment decisions for certain specialised services as part of its annual commissioning round.

Published
03 July 2015
From
NHS England press release
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.

Published
02 July 2015
From
Gilead press release

Filter by country